Occidental Petroleum’s Earnings Get Lift From Natural Gas Prices
U.S. oil major Occidental Petroleum (OXY) has announced a strong first-quarter profit due to a boost in natural gas prices. The Houston, Texas-based company reported earnings per share (EPS) of $0.87, which topped the consensus estimate among analysts of $0.78 U.S. The company’s revenue in the period totaled $6.80 billion U.S., which fell short of Wall Street forecasts that called for sales of $6.96 billion U.S.Management said that the quarterly profit was helped by higher crude oil production and favorable oil and natural gas prices. Brent crude oil, the international standard, averaged $74.98 U.S. a barrel during this year’s first quarter, while U.S. natural gas prices hit a two-year high on March 10.Occidental Petroleum credited its results largely to the lift it got from natural gas prices. The company said that its domestic realized price for total natural gas production rose 92% to $2.42 U.S. per thousand cubic feet. The company’s realized price for natural gas liquids (NGL) was $25.94 U.S. a barrel, up 19% quarter-over-quarter.Management also said that they lowered the company’s debt load by $2 billion U.S. during Q1 of this year. Occidental Petroleum had more than $25 billion U.S. of debt at the end of 2024 and executives at the company have made paying it down a priority.The stock of Occidental Petroleum has decreased 22% this year to trade at $39.01 U.S. a share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


